Ranitidine suppresses aluminium absorption in man

R. S C Rodger, Muralikrishna Golconda, D. J. Halls, J. B. Henderson, J. A H Forrest, A. I. Macdougall, G. S. Fell

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

1. Intragastric pH monitoring was performed before and after the single-blind administration of ranitidine or placebo (saline) in eight healthy subjects and four patients with end-stage renal disease who were on regular haemodialysis. 2. The subjects were studied on two occasions and were given aluminium hydroxide (1185 mg) orally 90 min after the administration of ranitidine or saline. 3. Plasma aluminium concentrations and, in normal men, urinary excretion of aluminium were monitored before and after the oral aluminium load. 4. Intragastric pH increased significantly with ranitidine but not with placebo (P < 0.001). Urinary aluminium excretion increased significantly after the administration of aluminium hydroxide during the placebo phase (P < 0.001) but not during the ranitidine phase. Plasma aluminium concentrations were higher in the patients with renal failure than in the normal subjects (P < 0.05), but were unchanged in both groups after the oral aluminium load. 5. This study shows that gastric pH is an important factor in the modulation of aluminium absorption in man, and indicates that reducing gastric acid secretion with ranitidine may reduce the toxicity of orally administered aluminium compounds.

Original languageEnglish (US)
Pages (from-to)505-508
Number of pages4
JournalClinical Science
Volume80
Issue number5
StatePublished - 1991
Externally publishedYes

Fingerprint

Ranitidine
Aluminum
Aluminum Hydroxide
Placebos
Aluminum Compounds
Gastric Acid
Chronic Kidney Failure
Renal Insufficiency
Renal Dialysis
Stomach
Healthy Volunteers

Keywords

  • Aluminium
  • Ranitidine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rodger, R. S. C., Golconda, M., Halls, D. J., Henderson, J. B., Forrest, J. A. H., Macdougall, A. I., & Fell, G. S. (1991). Ranitidine suppresses aluminium absorption in man. Clinical Science, 80(5), 505-508.

Ranitidine suppresses aluminium absorption in man. / Rodger, R. S C; Golconda, Muralikrishna; Halls, D. J.; Henderson, J. B.; Forrest, J. A H; Macdougall, A. I.; Fell, G. S.

In: Clinical Science, Vol. 80, No. 5, 1991, p. 505-508.

Research output: Contribution to journalArticle

Rodger, RSC, Golconda, M, Halls, DJ, Henderson, JB, Forrest, JAH, Macdougall, AI & Fell, GS 1991, 'Ranitidine suppresses aluminium absorption in man', Clinical Science, vol. 80, no. 5, pp. 505-508.
Rodger RSC, Golconda M, Halls DJ, Henderson JB, Forrest JAH, Macdougall AI et al. Ranitidine suppresses aluminium absorption in man. Clinical Science. 1991;80(5):505-508.
Rodger, R. S C ; Golconda, Muralikrishna ; Halls, D. J. ; Henderson, J. B. ; Forrest, J. A H ; Macdougall, A. I. ; Fell, G. S. / Ranitidine suppresses aluminium absorption in man. In: Clinical Science. 1991 ; Vol. 80, No. 5. pp. 505-508.
@article{cc949815ecc64330b67a7bd05e1c05d5,
title = "Ranitidine suppresses aluminium absorption in man",
abstract = "1. Intragastric pH monitoring was performed before and after the single-blind administration of ranitidine or placebo (saline) in eight healthy subjects and four patients with end-stage renal disease who were on regular haemodialysis. 2. The subjects were studied on two occasions and were given aluminium hydroxide (1185 mg) orally 90 min after the administration of ranitidine or saline. 3. Plasma aluminium concentrations and, in normal men, urinary excretion of aluminium were monitored before and after the oral aluminium load. 4. Intragastric pH increased significantly with ranitidine but not with placebo (P < 0.001). Urinary aluminium excretion increased significantly after the administration of aluminium hydroxide during the placebo phase (P < 0.001) but not during the ranitidine phase. Plasma aluminium concentrations were higher in the patients with renal failure than in the normal subjects (P < 0.05), but were unchanged in both groups after the oral aluminium load. 5. This study shows that gastric pH is an important factor in the modulation of aluminium absorption in man, and indicates that reducing gastric acid secretion with ranitidine may reduce the toxicity of orally administered aluminium compounds.",
keywords = "Aluminium, Ranitidine",
author = "Rodger, {R. S C} and Muralikrishna Golconda and Halls, {D. J.} and Henderson, {J. B.} and Forrest, {J. A H} and Macdougall, {A. I.} and Fell, {G. S.}",
year = "1991",
language = "English (US)",
volume = "80",
pages = "505--508",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "5",

}

TY - JOUR

T1 - Ranitidine suppresses aluminium absorption in man

AU - Rodger, R. S C

AU - Golconda, Muralikrishna

AU - Halls, D. J.

AU - Henderson, J. B.

AU - Forrest, J. A H

AU - Macdougall, A. I.

AU - Fell, G. S.

PY - 1991

Y1 - 1991

N2 - 1. Intragastric pH monitoring was performed before and after the single-blind administration of ranitidine or placebo (saline) in eight healthy subjects and four patients with end-stage renal disease who were on regular haemodialysis. 2. The subjects were studied on two occasions and were given aluminium hydroxide (1185 mg) orally 90 min after the administration of ranitidine or saline. 3. Plasma aluminium concentrations and, in normal men, urinary excretion of aluminium were monitored before and after the oral aluminium load. 4. Intragastric pH increased significantly with ranitidine but not with placebo (P < 0.001). Urinary aluminium excretion increased significantly after the administration of aluminium hydroxide during the placebo phase (P < 0.001) but not during the ranitidine phase. Plasma aluminium concentrations were higher in the patients with renal failure than in the normal subjects (P < 0.05), but were unchanged in both groups after the oral aluminium load. 5. This study shows that gastric pH is an important factor in the modulation of aluminium absorption in man, and indicates that reducing gastric acid secretion with ranitidine may reduce the toxicity of orally administered aluminium compounds.

AB - 1. Intragastric pH monitoring was performed before and after the single-blind administration of ranitidine or placebo (saline) in eight healthy subjects and four patients with end-stage renal disease who were on regular haemodialysis. 2. The subjects were studied on two occasions and were given aluminium hydroxide (1185 mg) orally 90 min after the administration of ranitidine or saline. 3. Plasma aluminium concentrations and, in normal men, urinary excretion of aluminium were monitored before and after the oral aluminium load. 4. Intragastric pH increased significantly with ranitidine but not with placebo (P < 0.001). Urinary aluminium excretion increased significantly after the administration of aluminium hydroxide during the placebo phase (P < 0.001) but not during the ranitidine phase. Plasma aluminium concentrations were higher in the patients with renal failure than in the normal subjects (P < 0.05), but were unchanged in both groups after the oral aluminium load. 5. This study shows that gastric pH is an important factor in the modulation of aluminium absorption in man, and indicates that reducing gastric acid secretion with ranitidine may reduce the toxicity of orally administered aluminium compounds.

KW - Aluminium

KW - Ranitidine

UR - http://www.scopus.com/inward/record.url?scp=0025874868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025874868&partnerID=8YFLogxK

M3 - Article

C2 - 1851692

AN - SCOPUS:0025874868

VL - 80

SP - 505

EP - 508

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 5

ER -